Uzi Sofer - 18 Mar 2026 Form 3 Insider Report for Alpha Tau Medical Ltd. (DRTS)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: DRTS
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 19:03:38 UTC
Source filing: View source filing
Reporting owner signature: /s/ Uzi Sofer

Key filing fact

Uzi Sofer filed Form 3 for Alpha Tau Medical Ltd. (DRTS) on 18 Mar 2026.

Key facts

This page summarizes Uzi Sofer's Form 3 filing for Alpha Tau Medical Ltd. (DRTS).
0 reported transactions and 15 derivative rows are listed below.
Accepted by SEC: 18 Mar 2026, 19:03.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001968053 Primary reporting owner

Sofer Uzi

Relationship: Chief Executive Officer, Director
Address: C/O ALPHA TAU MEDICAL LTD., JERUSALEM, ISRAEL
Signature: /s/ Uzi Sofer
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DRTS holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,250,941
Date: 18 Mar 2026
Ownership: Direct

DRTS holding

Restricted Share Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,680
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 54,318
Exercise price: $1.10
Footnotes: F2

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 54,318
Exercise price: $4.42
Footnotes: F2

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 174,770
Exercise price: $11.50
Footnotes: F2

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 8,945
Exercise price: $10.92
Footnotes: F2

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 229,089
Exercise price: $10.92
Footnotes: F2

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 10,657
Exercise price: $7.19
Footnotes: F2

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 250,933
Exercise price: $7.19
Footnotes: F2

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 46,905
Exercise price: $3.28
Footnotes: F2

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 1,102,653
Exercise price: $3.57
Footnotes: F2

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 43,257
Exercise price: $2.98
Footnotes: F2

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 763,843
Exercise price: $3.48
Footnotes: F2

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 24,460
Exercise price: $4.05
Footnotes: F2

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 674,238
Exercise price: $3.07
Footnotes: F2

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 15,527
Exercise price: $6.41
Footnotes: F3

DRTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 396,680
Exercise price: $7.32
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These ordinary shares represent restricted share units, which will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.

Footnote F2

These are options to acquire ordinary shares, which have fully vested as of the date hereof.

Footnote F3

These are options to acquire ordinary shares, which options will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.

Footnote F4

These are options to acquire ordinary shares, which options which vest in quarterly equal installments for a period of four years commencing January 1, 2026, subject to the Reporting Person's continued service.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .